Abstract
In an ex vivo rat ocular hypertension (OHT) model, the neurosteroid allopregnanolone (AlloP) exerts neuroprotective effects via enhancement of both GABAA receptors and autophagy. We now examine whether its enantiomer (ent-AlloP), which is largely inactive at GABA receptors, offers similar neuroprotection in ex vivo and in vivo rat OHT models. Ex vivo rat retinal preparations were incubated in a hyperbaric condition (10 and 75 mmHg) for 24 h. An in vivo ocular hypertension (OHT) model was induced by intracameral injection of polystyrene microbeads. We examined pharmacological effects of AlloP, ent-AlloP, picrotoxin (a GABAA receptor antagonist), and 3-MA (an autophagy inhibitor) histologically and biochemically. We found that both AlloP and ent-AlloP have marked neuroprotective effects in the retina, but effects of the unnatural enantiomer are independent of GABAA receptors. Electron microscopic analyses show that pressure elevation significantly increased autophagosomes (APs) in the nerve fiber layer and addition of AlloP also increased APs and degenerative autophagic vacuoles (AVds). ent-AlloP markedly increased APs and AVds compared to AlloP. Examination of LC3B-II and SQSTM1 protein levels using immunoblotting revealed that AlloP increased LC3B-II, and ent-AlloP further enhanced LC3B-II and suppressed SQSTM1, indicating that autophagy is a major mechanism underlying neuroprotection by ent-AlloP. In an rat in vivo OHT model, single intravitreal ent-AlloP injection prevented apoptotic cell death of retinal ganglion cells similar to AlloP. However, even in this model, ent-AlloP was more effective in activating autophagy than AlloP. We conclude that ent-AlloP may be a prototype of potential therapeutic for treatment of glaucoma as an autophagy enhancer without affecting GABA receptors.
Introduction
Glaucoma is one of the leading causes of irreversible blindness (Tham et al., 2014) and is characterized by selective degeneration of retinal ganglion cells (RGCs) (Quigley, 1999). Elevation of intraocular pressure (IOP) is considered as a significant risk factor for glaucoma (The AGIS Investigators, 2000). However, the molecular mechanisms of IOP induced RGC damage still remain elusive.
Neurosteroids are endogeneous steroids synthesized within the nervous system and can rapidly modulate neuronal excitability. The neurosteroid, allopregnanolone (AlloP) is a potent and effective positive allosteric modulator of GABAA receptors (). We previously reported that AlloP protected RGC from pressure-induced retinal injury in ex vivo rat retinas (, ). Because the neuroprotection by AlloP was inhibited by a specific GABAA antagonist, the neuroprotective effect of AlloP seemed likely mediated by GABAergic signaling.
However, neuroprotection by AlloP may involve mechanisms beyond GABAA receptor modulation. In addition to GABAergic functions, AlloP is found to promote autophagy in a murine Niemann-Pick Type C disease model () and in primary astrocyte cultures (). These findings suggest that autophagy activation may exert neuroprotective effects (). Indeed, we recently reported that in the retina AlloP activates autophagic flux and autophagy contributes to neuroprotection ().
Autophagy is a highly conserved system that supplies nutrients to survive starvation (). Autophagy also responds to cellular stresses such as accumulation of damaged organelles or pathogens. When autophagy begins, cytoplasmic constituents are sequestered by an expanding double-membrane structure, called the isolation membrane (Takeshige et al., 1992). The isolation membrane completes sequestration, and results in formation of a double-membrane vesicle (autophagosome, AP) (). APs then fuse with lysosomes to degrade their contents. These degrading structures are named degenerative autophagic vacuoles (AVds) or autolysosomes (; ; ) (Figure 1A). Autophagy is considered to play an important role in pathogenesis of neurodegenerative diseases including glaucoma (; ; Russo et al., 2015).
FIGURE 1
Because GABAA receptor-mediated actions might cause adverse effects in addition to neuroprotection, a compound similar to AlloP with selectivity for enhancing autophagic flux could be more desirable for therapeutic use. The synthetic enantiomer of AlloP (ent-AlloP) has weak actions on GABAA receptor signaling (Wittmer et al., 1996;
In the present study, we compared autophagic neuroprotection of ent-AlloP with AlloP using rat ex vivo and in vivo ocular hypertension (OHT) models.
Materials and Methods
All procedures were approved by the Akita University Animal Studies Committee, and performed in accordance with the guidelines of the Policies on the Use of Animals and Humans in Neuroscience Research.
Rat ex vivo Eyecup Preparation
28–32 day old male Sprague-Dawley rats were purchased from Charles River Laboratories International Inc. (Wilmington, MA) . The anterior half of enucleated eyes was removed, and the posterior eye cup was placed at the bottom of a 100 ml glass beaker filled with aCSF (artificial cerebrospinal fluid) containing (in mM): 124 NaCl, 5 KCl, 2 MgSO4, 2 CaCl2, 1.25 NaH2PO4, 22 NaHCO3, and 10 glucose, and incubated at 30°C for 24 h using a closed pressure-loading system (
In some experiments, AlloP (1 μM), ent-AlloP (1 μM), and 3-MA (10 mM) were administered in aCSF at the time of experiment, and incubated for 24 h. Eyecup preparations were preincubated with these drugs for 1 h at 30°C before pressure loading. After pressure loading at 10 mmHg or 75 mmHg for 24 h at 30°C, the pressure inside the chamber was gradually decreased.
Rat in vivo OHT Model
8 week old male Sprague-Dawley rats were purchased from Charles River Laboratories. Anesthesia was induced with an intraperitoneal injection of a mixture of medetomidine hydrochloride (Cat #133-17474, CAS.No 86347-15-1, Wako Pure Chemical Industries Ltd., Osaka, Japan, 0.15 mg/kg), midazolam (Cat#135-13791, CAS.No 58786-99-5, Wako Pure Chemical Industries Ltd., 2 mg/kg), and butorphanol tartrate (Cat#021-19001, CAS.No 86347-15-1, Wako Pure Chemical Industries Ltd., 2.5 mg/kg). A 10 μl PBS solution of sterile 6 μm polystyrene microbeads (1 × 107 microbeads/ml) (Molecular Probes, Eugene, OR, United States) was intracamerally injected using a single-step, sclero-corneal tunnel approach with a 35G-gauge nanoneedle (#LNAN-3505LM, Saito Medical Instruments Inc., Tokyo, Japan) connected to a 100 μl WPI Nanofil 100 microsyringe (World Precision Instruments, Inc., Sarasota, FL) as previously described (
One week after microbead injection, rats were randomly divided into a non-treated OHT group, an AlloP injection group, and an ent-AlloP injection group. A total volume of 1 μl of 20% w/v (2-Hydroxypropyl)-β-cyclodextrin (2HBCD) saline solution containing AlloP or ent-AlloP (0.05%, w/v) was vitreally injected under halothane anesthesia using a Hamilton syringe adapted with a 35 gauge (G) nanoneedle 1 week after the beads were injected. Non-treated OHT rats received sterile 1 μl 20% 2HBCD with phosphate buffered saline (PBS) (vehicle control). As a further control, 1 μl 20% 2HBCD was injected into the vitrous chamber 1 week after intracameral injection with 10 μl of PBS.
OHT was monitored preoperatively, and at 3 days, 1 week, 2 weeks or 3 weeks after bead injection. IOP was measured with a rebound tonometer (TonoLab, Icare Finland, Vantaa, Finland). The eyes were excised for TUNEL staining, flat-mount preparation, electron microscopy, and Western Blot 3 weeks after beads were injected. Electroretinograms (ERGs) were also recorded 3 weeks after bead injection.
Light Microscopy
After each experiment was complete, middle parts of retinal specimens were fixed in 1% paraform-aldehyde and 1.5% glutaraldehyde in 0.1 M phosphate buffer overnight at 4°C followed by post-fixation with 1% osmium tetroxide and 0.1 M phosphate buffer for 60 min as previously described (
Electron Microscopy
Ultrathin sections from retinal specimens embedded in epoxy resin were cut with a diamond knife and suspended over formvar-coated grids. After staining with uranyl acetate and lead citrate, ultrathin sections were viewed using a transmission electron microscope (H-7650, Hitachi High-Technologies Corp., Tokyo, Japan) according to previously described methods (
Data Analysis of Morphometry
According to previously described methods (
The density of degenerated cells in the GCL was calculated based on counting ten fields of 500 μm length (950–1,450 μm away from the center of the optic disc) in light micrographs (
The severity of neuronal damage was scored by light microscopy using a neuronal damage score (NDS). The NDS rates neuronal damage in the INL and the inner plexiform layer (IPL) on a 0-4 scale with 0 signifying no neuronal damage and 4 indicating very severe damage as described previously (
The number of axons was calculated based on measurement of five different optic nerves from five eyes per experimental condition, and data are presented as axon density per 100 μm2.
NFLT, density of degenerated cells in the GCL, NDS, were calculated based on measurement of 10 different areas from five eyes per experimental condition by three raters who were unaware of the experimental conditions as described above (
Preparation of Whole Mounted Retinas and Immunostaining
The retinas were detached from the pigment epithelium, flat-mounted, and fixed with 4% paraformaldehyde-0.1 M phosphate buffer overnight at 4°C. After rinse with PBS, retinas were immersed in 2% bovine serum albumin in PBS containing 0.5% Triton X-100, and incubated with rabbit anti-NeuN polyclonal antibody solution (Cat#ab104225, RRID:AB_10711153, Abcam, Cambridge, MA) (1:100) by gently shaking at 4°C, overnight. After rinsing 3 times using PBS, the retina was incubated in FITC-conjugated secondary antibody (goat anti-rabbit IgG (H&L) (Alexa Fluor®488) (Cat#ab150077, RRID:AB_2630356, abcam) (1:300). After rinsing 3 times with PBS, retinas were stretched on glass slides using 50% PBS and 50% glycerol. Retinal flat-mount preparations were imaged in each of the four defined retinal quadrants 4 mm from the optic nerve head using a confocal microscope according to previously described methods (
Apoptosis
According to previously described methods (
Western Blot Analysis
After homogenization of whole retinas, cellular proteins were extracted, separated by electrophoresis, transferred to nitrocellulose membranes and probed, as described previously (
The density of Western Blot bands of the lipid-anchored form of LC3B (LC3B-II) and SQSTM1 was quantitatively analyzed using Image-Pro Plus software as previously described (
Chemicals
AlloP was purchased from Wako Pure Chemical Industries, Ltd. (Cat#596-30841, CAS.NO 516-54-1; Osaka, Japan), and ent-AlloP (Wittmer et al., 1996) was synthesized by KK and DFC. All other chemicals were purchased from Sigma-Aldrich Corp. or Nacalai Tesque (Kyoto, Japan). AlloP and ent-AlloP were dissolved in DMSO as a 10 mM stock solution.
Electroretinogram Recording
At 3 weeks after the induction of elevated IOP, the positive components of the scotopic threshold response (p-STR), an indicator of RGC function, were measured according to our previous report (
Statistics
All analyses were performed using a biomedical statistical computer program (http://www.gen-info.osaka-u.ac.jp/MEPHAS/dunnett.html). For multiple comparisons with the control and other conditions, we used Dunnett’s or Tukey’s multiple comparison test. For comparison of two groups, we used Wilcoxon Rank-Sum Test.
Results
Effects of ent-AlloP on pressure-mediated retinal degeneration in an ex vivo model
Retinas exhibited normal appearance at 10 mmHg for 24 h incubation (Figure 2A) but showed axonal swelling in the nerve fiber layer (NFL) at 75 mmHg (Figure 2B). As we recently reported (
FIGURE 2

(A–F) Light micrographs of pressure-loaded retina. NFL is indicated with a short arrow. (A). 10 mmHg.(B). 75 mmHg. Arrowheads; axonal swelling. Arrow; blood vessel. (C). Administration of 1 μM AlloP at 75 mmHg.(D). Administration of 1 μM ent-AlloP at 75 mmHg. (E). Administration of 1 μM AlloP and 1 μM picrotoxin. (F). Administration of 1 μM ent-AlloP and 1 μM picrotoxin. Scale bars, 20 mm(G–J). RGC survival and neuroprotection with AlloP and ent-AlloP in pressure-loaded whole mounted retinas. (G). 10 mmHg.(H). 75 mmHg. (I). Administration of 1 μM AlloP at 75 mmHg. (J). Administration of 1 μM ent-AlloP at 75 mmHg. Scale bars, 200 μm (K). The number of immunopositive cells for anti-NeuN antibody in whole mount retinas (Tukey p < 0.05). (L–O). TUNEL staining. (L). 10 mmHg.(M). 75 mmHg. Administration of 1 μM AlloP (N). or 1 μM ent-AlloP (O). significantly suppressed the number of TUNEL-positive cells at 75 mmHg. Scale bars, 30 μm p. Quantitative analysis of the number of apoptotic RGCs per 200 μm of retina section (Tukey p < 0.05).
TABLE 1
| Condition | NFLT vs. RT (%) (p value vs. 75 mmHg) | NDS (p] | Damaged cells in GCL (p] |
|---|---|---|---|
| 10 mmHg | 1.3 ± 0.7 (Reference) | 0.2 ± 0.4 (Reference) | 1.3 ± 1.5 (Reference) |
| 75 mmHg | 11.3 ± 1.9 [-] | 0.7 ± 0.5 [-] | 16.2 ± 5.3 [-] |
| 75 mmHg + 1 μM AlloP | 1.7 ± 0.7 (*p < 0.05) | 0.2 ± 0.4 (p > 0.05) | 2.0 ± 1.7 (*p < 0.05) |
| 75 mmHg + 1 μM ent-AlloP | 1.6 ± 0.6 (*p < 0.05) | 0.3 ± 0.5 (p > 0.05) | 1.9 ± 1.2 (*p < 0.05) |
| 75 mmHg + 1 μM AlloP + 1 μM Picro | 3.8 ± 2.6 (*p < 0.05) | 3.0 ± 0.8 (*p < 0.05) | 23.9 ± 6.6 (*p < 0.05) |
| 75 mmHg + 1 μM ent-AlloP + 1 μM Picro | 1.5 ± 0.6 (*p < 0.05) | 0.3 ± 0.5 (p > 0.05) | 2.1 ± 1.1 (*p < 0.05) |
Morphological changes of retinas after pressure-loading and neurosteroids treatment.
Values are expressed as mean ± SD. NFLT vs. retinal thickness (RT) (%) means the NFLT percentage of total RT. Number of degenerated cells in the GCL was counted per 250 μm of retina. Statistical significance in each parameter were calculated using Dunnett’s test.
ent-AlloP Preserves Neuronal Nuclear Antigen Under High Pressure
In whole mounted retinas, pressure elevation decreased cells positive for NeuN. Figure 2G demonstrates confocal images of NeuN-labeled RGCs of a control eye incubated at 10 mmHg. As previously reported (
ent-AlloP Prevents Pressure-induced Apoptosis
As previously reported (
Autophagy Vacuoles Induced by High Pressure and Effects of ent-AlloP
We have observed that in the NFL AlloP robustly increases autophagosomes (APs) whereas APs are minimal at control pressure (10 mmHg, Figures 3A,E–G) or elevated pressure (70 mmHg) without AlloP (Figures 3B,H–J). We also observed that AlloP significantly increases degenerative autophagic vacuoles (AVds) (Figures 3C,K,L) as reported previously (
FIGURE 3

Electron micrographic (A–O) and Western Blot analyses (P,Q) of ex vivo retinas. (A–D) Low magnification of the NFL at 10 mmHg (A), 75 mmHg (B), 75 mmHg with AlloP administration (C), and 75 mmHg with ent-AlloP administration (D). Mu, Müller cell. (E–G) AVds (double arrows in e) and AP (single arrow in F) in the NFL at 10 mmHg.(H–J) AVds (double arrows in H) and AP (single arrow in J) in the NFL at 75 mmHg. (K,L) Administration of AlloP (1 μM) at 75 mmHg. AVds are indicated with double arrows. (M) Administration of ent-AlloP (1 μM) at 75 mmHg. Double arrows, AVd. (N) The density of AP per 50 μm2 of retina. (Tukey p < 0.05). (O) The density of AVd per 50 μm2 of retina (Tukey p < 0.05). P-1. Representative immunoblotting for LC3B and actin. P-2. Relative densitometry analysis of LC3B-II expression (n = 4 per experiment, Tukey p < 0.05). Q-1. Representative immunoblotting for SQSTM1 and actin. Q-2. Relative densitometry analysis of SQSTM1 expression (n = 4 per experiment, Tukey p < 0.05).
Autophagy Markers and Effects of ent-AlloP on Autophagy Flow
LC3B protein plays a critical role in autophagy, and the lipidated form of LC3B (LC3B-II), an indicator of autophagosome formation, displayed a band at approximately 14 kDa. Quantitative Western Blot analysis demonstrated that administration of both neurosteroids significantly increased LC3B-II expression compared to drug-free pressure elevation (Figure 3P–1). However, the increase is more robust with ent-AlloP, indicating again that ent-AlloP is a more efficient enhancer of autophagy than AlloP (Figure 3P-2).
We next examined expressional changes of SQSTM1, a widely used predictor of autophagic flux that is incorporated into mature autophagosomes and accumulates when autophagic flux is inhibited (
3-MA Blocks Autophagy and Inhibits Neuroprotective Effects of Ent-AlloP
To determine whether autophagy plays a key role in retinal protection by ent-AlloP, we examined 3-methyladenine (3-MA), an inhibitor of autophagic flux. At 75 mmHg, 3-MA did not alter neuroprotection by AlloP (Figure 4A), but dampened the effects of ent-AlloP (Figure 4B). We also found that 3-MA alone was neurodegenerative at both 75 mmHg (Figure 4C) and 10 mmHg (Figure 4D), indicating that autophagy is important for maintaining retinal integrity even under control conditions. A combination of ent-AlloP and 3-MA significantly increased damaged cells in the GCL compared to controls at 75 mmHg (p < 0.05) and overcame the protective effects of ent-AlloP at high pressure. Structural changes induced by pressure elevation and administration of neurosteroids or 3-MA are analyzed in Table 2.
FIGURE 4

(A–D) Light micrographs showing effects of pressure elevation, neurosteroids, and 3-MA on retinal morphology. NFL is indicated with a short arrow. (A) Administration of 10 mM 3-MA showed no differences in the retina incubated with 1 μM AlloP at 75 mmHg.(B) Administration of 10 mM 3-MA dampened protective effects of 1 μM ent-AlloP at 75 mmHg. Arrowheads; axonal swelling. Arrows; RGC degeneration. (C) 3-MA (10 mM) alone induced severe damage at 75 mmHg. Arrowheads; axonal swelling. Arrows; RGC degeneration. (D) 3-MA (10 mM) also induced degeneration at 10 mmHg. Arrows; RGC degeneration or vacuoles in GCL. Scale bars, 20 μm. E-1. Representative Western Blot analyses of LC3B proteins in pressure-loaded retinas (75 mmHg) treated with 1 μM ent-AlloP alone or with 1 μM ent-AlloP and 10 mM 3-MA. E-2. Relative densitometry analysis of LC3B-II expression in the retina incubated with ent-AlloP or with 1 μM ent-AlloP and 10 mM 3-MA at 75 mmHg (n = 4 per experiment, Wilcoxon Rank-Sum Test p < 0.05). F-1. Representative Western Blot analyses of SQSTM1 proteins in pressure-loaded retinas (75 mmHg) treated with 1 μM ent-AlloP alone or with 1 μM ent-AlloP and 10 mM 3-MA. F-2. Relative densitometry analysis of SQSTM1 expression. Administration of 10 mM 3-MA significantly increased SQSTM1 expression in the retina incubated with ent-AlloP at 75 mmHg (n = 4 per experiment, Wilcoxon Rank-Sum Test, p < 0.05).
TABLE 2
| Condition | NFLT vs. RT (%) (p value vs. 75 mmHg) | NDS (p) | Damaged cells in GCL (p) |
|---|---|---|---|
| 75 mmHg + 10 mM 3-MA | 1.4 ± 1.0 (Reference) | 1.4 ± 0.5 (Reference) | 17.7 ± 3.4 (Reference) |
| 75 mmHg + 1 μM AlloP + 10 mM 3-MA | 1.8 ± 0.4 (p > 0.05) | 0.3 ± 0.5 (*p < 0.05) | 4.9 ± 2.1 (*p < 0.05) |
| 75 mmHg + 1 μM ent-AlloP + 10 mM 3-MA | 11.4 ± 0.8 (*p < 0.05) | 1.4 ± 0.5 (p > 0.05) | 17.1 ± 6.0 (p > 0.05) |
Morphological changes of retinas after 3-MA and neurosteroids treatment.
Values are expressed as mean ± SD. NFLT vs. retinal thickness (RT) (%) means the NFLT percentage of total RT. Number of degenerated cells in the GCL was counted per 250 μm of retina. Statistical significance in each parameter were calculated using Dunnett’s test.
We also examined whether 3-MA altered the effects of ent-AlloP on autophagic markers, and found that upregulation of LC3B-II levels induced by ent-AlloP was dampened by 3-MA (Figures 4E-1, 4E-2). Also, the decrease of SQSTM1 levels induced by ent-AlloP at 75 mmHg was reversed by 3-MA (Figures 4F–1, 4F-2). These findings indicate that ent-AlloP likely acts by enhancing autophagic flow.
Rat in vivo OHT Model Induced by Intracameral Injection of Microbeads
Ocular hypertension (OHT) was induced by injection of sterile 6 μm polystyrene microbeads into the anterior chamber. AlloP or ent-AlloP was administered as a one-time intravitreal injection 1 week following bead injection. Three weeks after bead injections, IOP increased to 26.1 ± 3.1 mmHg in non-treated OHT eyes compared to 10.4 ± 1.0 mmHg in control eyes, whereas it was 27.1 ± 3.1 mmHg in eyes treated with AlloP, similar to what we reported previously (
FIGURE 5

Effects of IOP and neurosteroids on RGC or axonal survival. (A) IOP profiles. An arrow marks the day when drugs were injected (day 7). (B–E) TUNEL staining. (B) Control eye. c. Non-treated OHT eye. (D,E) Administration of 1 μM AlloP (D) or 1 μM ent-AlloP (E) in OHT eyes. Scale bars, 30 μm. (F) The number of TUNEL-positive RGCs per 200 μm of retinal sections (Tukey p < 0.05). (G–J) Confocal images of NeuN-labeled RGCs. (G) Control eye. (H) Microbead-injected OHT eye without neurosteroid administration. (I,J) Administration of 1 μM AlloP (I) or 1 μM ent-AlloP (J). Scale bars, 200 μm. (K) The density of immunopositive cells for NeuN antibody in the whole mount retina under each condition (Tukey p < 0.05). (L–O) Light micrographs of the optic nerves 3 weeks after microbead injection. (L) Control eye. (M) OHT. (N,O) Administration of 1 μM AlloP (N) or 1 μM ent-AlloP (O). Scale bars, 10 μm. (P) Effects of IOP elevation, AlloP and ent-AlloP on Axon number in whole mount retinas (Tukey p < 0.05).
In spite of sustained elevation of IOP, both neurosteroids are effective neuroprotectants. Apoptosis activation as detected as TUNEL-positive cells in the GCL was clearly suppressed by ent-AlloP and the efficacy was comparable with AlloP (Figures 5B–F). Furthermore, the reduction of retinal ganglion cells (RGSs) by IOP elevation was prevented by ent-AlloP and the efficacy was comparable to AlloP (Figures 5G–K). Moreover, axonal loss in the optic nerve by IOP elevation was well prevented by both neurosteroids (Figures 5L–P).
Autophagy Vacuoles and Markers by IOP Elevation and Effects of ent-AlloP
Effects of neurosteroids on changes in autophagy vacuoles and markers following IOP elevation are similar to those observed in the ex vivo model. Consistent with our previous study (
FIGURE 6

Electron micrographs and Western Blotting in in vivo OHT eyes. (A–D) Electron micrographs of the NFL. (A-1,A-2,A-3). Control eyes. NFL, nerve fiber layer. A-1. Low magnification. (A-1,A-3). AVd (double arrows in A-2) and AP (single arrow in A-3). B-1, B-2, B-3. Non-treated OHT eye. B-1. Low magnification. B-2, B-3. AVd (B-2) indicated by double arrows and AP (B-3) indicated by single arrow. C-1, C-2, C-3. OHT eyes treated with AlloP. C-1. Low magnification. C-2, C-3. AVds indicated by double arrows. D-1, D-2, D3. OHT eyes treated with ent-AlloP. d-1. Low magnification. D-2, D-3. AVds (double arrows). E-1 and E-2. The density of APs (e-1) and AVds (E-2) (n = 10 per experiment, Tukey p < 0.05). f-i. Electron micrographs of optic nerves. f. Control eyes. G-1, G-2, G-3. OHT eye. G-1. Low magnification. g-2. AP (arrow in G-2). G-3. AP. H-1, H-2, H-3. OHT eye treated with AlloP. H-1. Low magnification. H-2. AVd (double arrows). H-3. AP (single arrow). I-1, I-2, I-3. OHT eye treated with ent-AlloP. I-1. Low magnification. I-2 and I-3. AVds (double arrows). J. The density of APs (J-1) and AVds (J-2) (Tukey p < 0.05). (K, L) Western Blot Analysis. K-1. Representative immunoblotting for LC3B and actin. K-2. Relative densitometry analysis of LC3B-II expression (n = 4 per experiment, Tukey p < 0.05). L-1. Representative immunoblotting for SQSTM1 and actin. L-2. Relative densitometry analysis of SQSTM1 expression (n = 4 per experiment, Tukey p < 0.05).
We have shown that AlloP increases LC3B-II expression compared to drug-free pressure elevation (Figures 6K-1, K-2). Now we found that the increase was more robust with ent-AlloP, indicating again that ent-AlloP is a more efficient accelerator of autophagy than AlloP.
Increased expression of SQSTM1 by elevated pressure was partially dampened by AlloP as we showed previously (
Intravitreal Neurosteroid Injection Preserves Scotopic Threshold Responses in Rat in vivo OHT Model.
3 weeks after bead injections, the positive amplitude of the p-STR was significantly decreased in OHT eyes compared to control eyes (Figures 7A-1, A-2). A single intravitreal injection of AlloP and ent-AlloP prevented the decrease in p-STR amplitude with similar effects of the two neurosteroids (Figures 7A-3, A-4). A quantitative measurement of corrected p-STR is summarized in Figure 7B.
FIGURE 7

ERG analyses in in vivo OHT eyes. A-1 to A-4. Representative ERG tracing in each experimental condition 3 weeks after intracameral bead injection. A-1. Control. A-2. OHT. A-3. Intravitreal administration of AlloP. A-4. Intravitreal administration of ent-AlloP. (B) Comparison of corrected p-STR amplitudes obtained from each experimental condition (n = 4 per each experiment, Tukey p < 0.05).
Discussion
Using ex vivo and in vivo OHT models, we recently reported that AlloP enhances autophagy flow and found that this enhancement results in neuroprotection (
In this study, we made several important observations. First, we found that ent-AlloP protects the retina from high pressure damage in both ex vivo and in vivo models. Of importance is that the neuroprotection of ent-AlloP matches that of AlloP, supporting its potential as a therapeutic approach. Second, different from AlloP, however, neuroprotection by ent-AlloP in the ex vivo system was still observed in the presence of PTX, indicating that the mechanism underlying the neuroprotection is, as expected, independent of GABAA receptors. This finding also implies that ent-AlloP could be more neuroprotective than AlloP, because it is expected that the neuroprotection remains even under conditions of ‘disinhibition’, which may cause various neuronal problems (Knutson et al., 2015).
Third, the present data demonstrate that the therapeutic potential of ent-AlloP involves autophagy enhancement. While apoptosis kills RGCs in glaucoma (
Given that autophagy is observed in glaucoma models, it is important to consider whether autophagy is neuroprotective or neurodegenerative. We addressed this issue using 3-MA, an agent that blocks autophagy by inhibiting class III phosphoinositide 3-kinase (PI3K), an enzyme required for membrane dynamics in autophagic vesicle trafficking and autophagosome formation (Seglen and Gordon, 1982).
Similar to a model of dementia, in which inhibition of early autophagy with 3-MA is neuroprotective (
We have reported that AlloP enhances autophagy in our OHT models (
To determine whether ent-AlloP induced neuroprotective autophagy, we examined the pharmacological effects of 3-MA on LC3B proteins. We found that 3-MA attenuated LC3B-II upregulation induced by ent-AlloP (Figure 3E). 3-MA also upregulated SQSTM1 levels in spite of the presence of ent-AlloP (Figure 3F). It is known that SQSTM1 levels inversely correlate with autophagy activity (
Previously, in the ex vivo glaucoma model we showed that simultaneous administration of AlloP with the autophagy inhibitor bafilomycin A1 induced retinal degeneration at 75 mmHg (
While we used 3-MA to inhibit autophagy, it is important to note that prior studies indicate that this agent has complex effects. Wu et al. (2010) reported that 3-MA suppresses starvation-induced autophagy in cultured mouse embryonic fibroblasts but paradoxically promotes autophagy in nutrient-rich conditions. Similar to nutrient deprivation, acute IOP elevation is a substantial cellular stress to neurons and induces mitochondrial dysfunction, resulting in energy deficiency (
We conclude that ent-AlloP and AlloP, may promote neuroprotection in glaucomatous damage but that ent-AlloP is more selective and effective in activating autophagy, possibly providing unique advantages in different clinical situations. These results also have implications for the development of neurosteroids as treatments for other neurodegenerative disorders. Future studies should determine the cellular mechanisms by which autophagy enhancement protects retinal neurons from glaucoma (
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
The animal study was reviewed and approved by Akita University Animal Studies Committee in accordance with the guidelines of the Policies on the Use of Animals and Humans in Neuroscience Research (a-1-3006).
Author contributions
MI, YI, CFZ, and DC designed the experiments. MI was a major contributor to animal experimentation. YI, CZ, DC, TN, HK, KS, and TY contributed with the necessary help to carry out the ex vivo and in vivo experiments. MI and YI wrote the original draft. CZ and DC gave scientific advice and participated in the writing of the manuscript. All authors contributed to the data interpretation, drafting of the manuscript, critically revising the manuscript, and approving its final version.
Funding
This work was supported by the Japan Society for the Promotion of Science 18K09438; National Institute of Mental Health MH101874 and MH122379 and the Bantly Foundation.
Acknowledgments
Authors thank Sanae Takaseki, and Yoko Hayami for technical supports.
Conflict of interest
MI receives grants from Nidek Co., Ltd. TN receives grants from Wakamoto Pharmaceutical Co., Ltd. and Nidek Co., Ltd., grants and personal fees from Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Topcon Corporation. HK receives grants and personal fees from Wakamoto Pharmaceutical Co., Ltd., Nidek Co., Ltd., Santen Pharmaceutical Co., Ltd. and Senju Pharmaceutical Co., Ltd. KS receives grants from Santen Pharmaceutical Co., Ltd., Kowa Company, Ltd., DAIICHI SANKYO Company, Ltd., ROHTO Pharmaceutical Co.,Ltd. Wakamoto Pharmaceutical Co., Ltd., Topcon Corporation, and Senju Pharmaceutical Co., Ltd. CZ serves on the Scientific Advisory Board of Sage Therapeutics. CZ and DC own stock in Sage Therapeutics.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.855779/full#supplementary-material
References
1
AlakoskelaJ. M.CoveyD. F.KinnunenP. K. (2007). Lack of Enantiomeric Specificity in the Effects of Anesthetic Steroids on Lipid Bilayers. Biochim. Biophys. Acta1768, 131–145. 10.1016/j.bbamem.2006.07.011
2
BjørkøyG.LamarkT.PankivS.ØvervatnA.BrechA.JohansenT. (2009). Monitoring Autophagic Degradation of p62/SQSTM1. Methods Enzymol.452, 181–197. 10.1016/S0076-6879(08)03612-4
3
BoyaP. (2017). Why Autophagy Is Good for Retinal Ganglion Cells?Eye (Lond)31, 185–190. 10.1038/eye.2016.278
4
ChenS.YaoL. (2021). Autophagy Inhibitor Potentiates the Antitumor Efficacy of Apatinib in Uterine Sarcoma by Stimulating PI3K/Akt/mTOR Pathway. Cancer Chemother. Pharmacol.88, 323–334. 10.1007/s00280-021-04291-5
5
CoveyD. F. (2009). Ent-Steroids: Novel Tools for Studies of Signaling Pathways. Steroids74, 577–585. 10.1016/j.steroids.2008.11.019
6
de WaalE. J.Vreeling-SindelárováH.SchellensJ. P.JamesJ. (1986). Starvation-induced Microautophagic Vacuoles in Rat Myocardial Cells. Cell Biol. Int. Rep10, 527–533. 10.1016/0309-1651(86)90027-5
7
DengS.WangM.YanZ.TianZ.ChenH.YangX.et al (2013). Autophagy in Retinal Ganglion Cells in a Rhesus Monkey Chronic Hypertensive Glaucoma Model. PLoS ONE8, e77100. 10.1371/journal.pone.0077100
8
EskelinenE. L. (2005). Maturation of Autophagic Vacuoles in Mammalian Cells. Autophagy1, 1–10. 10.4161/auto.1.1.1270
9
FujiiC.ZorumskiC. F.IzumiY. (2021). Ethanol, Neurosteroids and Cellular Stress Responses: Impact on central Nervous System Toxicity, Inflammation and Autophagy. Neurosci. Biobehav. Rev.124, 168–178. 10.1016/j.neubiorev.2021.01.026
10
GuoL.MossS. E.AlexanderR. A.AliR. R.FitzkeF. W.CordeiroM. F. (2005). Retinal Ganglion Cell Apoptosis in Glaucoma Is Related to Intraocular Pressure and IOP-Induced Effects on Extracellular Matrix. Invest. Ophthalmol. Vis. Sci.46, 175–182. 10.1167/iovs.04-0832
11
HasegawaJ.MaejimaI.IwamotoR.YoshimoriT. (2015). Selective Autophagy: Lysophagy. Methods75, 128–132. 10.1016/j.ymeth.2014.12.014
12
HuY.WittmerL. L.KalkbrennerM.EversA. S.ZorumskiC. F.CoveyD. F.et al (1997). Neurosteroid analogues. Part 5.1 Enantiomers of neuroactive steroids and benz[e]indenes: total synthesis, electrophysiological effects on GABAA receptor function and anesthetic actions in tadpoles. J. Chem. Soc. Perkin Trans.1, 3665–3672. 10.1039/a703212i
13
IshikawaM.TakasekiS.YoshitomiT.CoveyD. F.ZorumskiC. F.IzumiY. (2021). The Neurosteroid Allopregnanolone Protects Retinal Neurons by Effects on Autophagy and GABRs/GABAA Receptors in Rat Glaucoma Models. Autophagy17, 743–760. 10.1080/15548627.2020.1731270
14
IshikawaM.YoshitomiT.CoveyD. F.ZorumskiC. F.IzumiY. (2016). TSPO Activation Modulates the Effects of High Pressure in a Rat Ex Vivo Glaucoma Model. Neuropharmacology111, 142–159. 10.1016/j.neuropharm.2016.09.001
15
IshikawaM.YoshitomiT.ZorumskiC. F.IzumiY. (2014). Neurosteroids Are Endogenous Neuroprotectants in an Ex Vivo Glaucoma Model. Invest. Ophthalmol. Vis. Sci.55, 8531–8541. 10.1167/iovs.14-15624
16
JohansenT.LamarkT. (2011). Selective Autophagy Mediated by Autophagic Adapter Proteins. Autophagy7, 279–296. 10.4161/auto.7.3.14487
17
JuW. K.KimK. Y.LindseyJ. D.AngertM.Duong-PolkK. X.ScottR. T.et al (2008). Intraocular Pressure Elevation Induces Mitochondrial Fission and Triggers OPA1 Release in Glaucomatous Optic Nerve. Invest. Ophthalmol. Vis. Sci.49, 4903–4911. 10.1167/iovs.07-1661
18
KabeyaY.MizushimaN.UenoT.YamamotoA.KirisakoT.NodaT.et al (2000). LC3, a Mammalian Homologue of Yeast Apg8p, Is Localized in Autophagosome Membranes after Processing. EMBO J.19, 5720–5728. 10.1093/emboj/19.21.5720
19
KatoK.SasakiN.ShastryB. S. (2012). Retinal Ganglion Cell (RGC) Death in Glaucomatous Beagles Is Not Associated with Mutations in P53 and NTF4 Genes. Vet. Ophthalmol.15, 8–12. 10.1111/j.1463-5224.2012.01024.x
20
KimH. N.LeeS. J.KohJ. Y. (2012). The Neurosteroids, Allopregnanolone and Progesterone, Induce Autophagy in Cultured Astrocytes. Neurochem. Int.60, 125–133. 10.1016/j.neuint.2011.11.015
21
KitaokaY.MunemasaY.KojimaK.HiranoA.UenoS.TakagiH. (2013). Axonal protection by Nmnat3 Overexpression with Involvement of Autophagy in Optic Nerve Degeneration. Cell Death Dis4, e860. 10.1038/cddis.2013.391
22
KnutsonK. M.Dal MonteO.SchintuS.WassermannE. M.RaymontV.GrafmanJ.et al (2015). Areas of Brain Damage Underlying Increased Reports of Behavioral Disinhibition. J. Neuropsychiatry Clin. Neurosci.7, 193–198. 10.1176/appi.neuropsych.14060126
23
KochJ. C.KnöferleJ.TöngesL.OstendorfT.BährM.LingorP. (2010). Acute Axonal Degeneration In Vivo Is Attenuated by Inhibition of Autophagy in a Calcium-dependent Manner. Autophagy6, 658–659. 10.4161/auto.6.5.12188
24
LangmadeS. J.GaleS. E.FrolovA.MohriI.SuzukiK.MellonS. H.et al (2006). Pregnane X Receptor (PXR) Activation: a Mechanism for Neuroprotection in a Mouse Model of Niemann-Pick C Disease. Proc. Natl. Acad. Sci. U S A.103, 13807–13812. 10.1073/pnas.0606218103
25
LeeJ. A.GaoF. B. (2009). Inhibition of Autophagy Induction Delays Neuronal Cell Loss Caused by Dysfunctional ESCRT-III in Frontotemporal Dementia. J. Neurosci.29, 8506–8511. 10.1523/JNEUROSCI.0924-09.2009
26
LiaoG.CheungS.GaleanoJ.JiA. X.QinQ.BiX. (2009). Allopregnanolone Treatment Delays Cholesterol Accumulation and Reduces Autophagic/lysosomal Dysfunction and Inflammation in Npc1-/- Mouse Brain. Brain Res.1270, 140–151. 10.1016/j.brainres.2009.03.027
27
LitonP. B.LinY.GonzalezP.EpsteinD. L. (2009). Potential Role of Lysosomal Dysfunction in the Pathogenesis of Primary Open Angle Glaucoma. Autophagy5, 122–124. 10.4161/auto.5.1.7304
28
LiuX.TianF.WangS.WangF.XiongL. (2017). Astrocyte Autophagy Flux Protects Neurons against Oxygen-Glucose Deprivation and Ischemic/Reperfusion Injury. Rejuvenation Res.21, 405–415. 10.1089/rej.2017.1999
29
LocciA.PinnaG. (2017). Neurosteroid Biosynthesis Down-Regulation and Changes in GABAA Receptor Subunit Composition: a Biomarker axis in Stress-Induced Cognitive and Emotional Impairment. Br. J. Pharmacol.174, 3226–3241. 10.1111/bph.13843
30
MizushimaN. (2007). Autophagy: Process and Function. Genes Dev.21, 2861–2873. 10.1101/gad.1599207
31
MizushimaN.YoshimoriT. (2007). How to Interpret LC3 Immunoblotting. Autophagy3, 542–545. 10.4161/auto.4600
32
MunemasaY.KitaokaY. (2015). Autophagy in Axonal Degeneration in Glaucomatous Optic Neuropathy. Prog. Retin. Eye Res.47, 1–18. 10.1016/j.preteyeres.2015.03.002
33
OkuH.KidaT.HorieT.TakiK.MimuraM.KojimaS.et al (2019). Tau Is Involved in Death of Retinal Ganglion Cells of Rats from Optic Nerve Crush. Invest. Ophthalmol. Vis. Sci.60, 2380–2387. 10.1167/iovs.19-26683
34
ParkH. L.KimJ. H.ParkC. K. (2018). Different Contributions of Autophagy to Retinal Ganglion Cell Death in the Diabetic and Glaucomatous Retinas. Sci. Rep.8, 13321. 10.1038/s41598-018-30165-7
35
ParkH. Y.KimJ. H.ParkC. K. (2012). Activation of Autophagy Induces Retinal Ganglion Cell Death in a Chronic Hypertensive Glaucoma Model. Cell Death Dis.3, e290. 10.1038/cddis.2012.26
36
PirasA.GianettoD.ConteD.BosoneA.VercelliA. (2011). Activation of autophagy in a rat model of retinal ischemia following high intraocular pressure. PLoS One 6:e22514. 10.1371/journal.pone.0022514
37
QuigleyH. A. (1999). Neuronal Death in Glaucoma. Prog. Retin. Eye Res.18, 39–57. 10.1016/S1350-9462(98)00014-7
38
Rodríguez-MuelaN.GermainF.MariñoG.FitzeP. S.BoyaP. (2012). Autophagy Promotes Survival of Retinal Ganglion Cells after Optic Nerve Axotomy in Mice. Cell Death Differ19, 162–169. 10.1038/cdd.2011.88
39
RussoR.NucciC.CorasanitiM. T.BagettaG.MorroneL. A. (2015). Autophagy Dysregulation and the Fate of Retinal Ganglion Cells in Glaucomatous Optic Neuropathy. Prog. Brain Res.220, 87–105. 10.1016/bs.pbr.2015.04.009
40
RussoR.VaranoG. P.AdornettoA.NazioF.TettamantiG.GirardelloR.et al (2018). Rapamycin and Fasting Sustain Autophagy Response Activated by Ischemia/reperfusion Injury and Promote Retinal Ganglion Cell Survival. Cel Death Dis9, 981. 10.1038/s41419-018-1044-5
41
SeglenP. O.GordonP. B. (1982). 3-Methyladenine: Specific Inhibitor of Autophagic/lysosomal Protein Degradation in Isolated Rat Hepatocytes. Proc. Natl. Acad. Sci. U S A.79, 1889–1892. 10.1073/pnas.79.6.1889
42
SpaldingK. L.DharmarajanA. M.HarveyA. R. (2005). Caspase-independent Retinal Ganglion Cell Death after Target Ablation in the Neonatal Rat. Eur. J. Neurosci.21, 33–45. 10.1111/j.1460-9568.2004.03826.x
43
SuW.LiZ.JiaY.ZhuoY. (2014). Rapamycin Is Neuroprotective in a Rat Chronic Hypertensive Glaucoma Model. PLoS ONE9, e99719. 10.1371/journal.pone.0099719
44
TakeshigeK.BabaM.TsuboiS.NodaT.OhsumiY. (1992). Autophagy in Yeast Demonstrated with Proteinase-Deficient Mutants and Conditions for its Induction. J. Cel Biol.119, 301–311. 10.1083/jcb.119.2.301
45
ThamY. C.LiX.WongT. Y.QuigleyH. A.AungT.ChengC. Y. (2014). Global Prevalence of Glaucoma and Projections of Glaucoma burden through 2040: a Systematic Review and Meta-Analysis. Ophthalmology121, 2081–2090. 10.1016/j.ophtha.2014.05.013
46
The AGIS Investigators (2000). The Advanced Glaucoma Intervention Study (AGIS): 7. The Relationship between Control of Intraocular Pressure and Visual Field deterioration.the AGIS Investigators. Am. J. Ophthalmol.130, 429–440. 10.1016/S0002-9394(00)00538-9
47
WangY.HuangC.ZhangH.WuR. (2015). Autophagy in Glaucoma: Crosstalk with Apoptosis and its Implications. Brain Res. Bull.117, 1–9. 10.1016/j.brainresbull.2015.06.001
48
WittmerL. L.HuY.KalkbrennerM.EversA. S.ZorumskiC. F.CoveyD. F. (1996). Enantioselectivity of Steroid-Induced Gamma-Aminobutyric acidA Receptor Modulation and Anesthesia. Mol. Pharmacol.50, 1581–1586. Available at https://europepmc.org/article/MED/8967980.
49
WuY. T.TanH. L.ShuiG.BauvyC.HuangQ.WenkM. R.et al (2010). Dual Role of 3-methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-kinase. J. Biol. Chem.285, 10850–10861. 10.1074/jbc.M109.080796
50
XilouriM.PapazafiriP. (2008). Induction of Akt by Endogenous Neurosteroids and Calcium Sequestration in P19 Derived Neurons. Neurotox. Res.13, 209–219. 10.1007/BF03033504
Summary
Keywords
autophagy, allopregnanolone, enantiomer, glaucoma, intraocular pressure, neurosteroid
Citation
Ishikawa M, Nakazawa T, Kunikata H, Sato K, Yoshitomi T, Krishnan K, Covey DF, Zorumski CF and Izumi Y (2022) The Enantiomer of Allopregnanolone Prevents Pressure-Mediated Retinal Degeneration Via Autophagy. Front. Pharmacol. 13:855779. doi: 10.3389/fphar.2022.855779
Received
15 January 2022
Accepted
18 February 2022
Published
16 March 2022
Volume
13 - 2022
Edited by
Afsun Sahin, Koç University, Turkey
Reviewed by
Kenji Sakamoto, Teikyo University, Japan
Oyuna S. Kozhevnikova, Institute of Cytology and Genetics (RAS), Russia
Updates

Check for updates
Copyright
© 2022 Ishikawa, Nakazawa, Kunikata, Sato, Yoshitomi, Krishnan, Covey, Zorumski and Izumi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Makoto Ishikawa, makoto.ishikawa.c2@tohoku.ac.jp
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.